FDA expands use of Gilenya to pediatric patients with MS

Author(s):

gilenya pediatric patients ms

On May 11, the U.S. Food and Drug Administration (FDA) approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first drug FDA has approved for treating MS in pediatric patients.

Read more via FDA.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here